International Assets Investment Management LLC Boosts Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

International Assets Investment Management LLC lifted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 9,382.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,379 shares of the biotechnology company’s stock after purchasing an additional 11,259 shares during the period. International Assets Investment Management LLC’s holdings in Sarepta Therapeutics were worth $1,097,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of SRPT. Montag A & Associates Inc. acquired a new stake in Sarepta Therapeutics in the 3rd quarter worth about $30,000. Cary Street Partners Investment Advisory LLC lifted its position in shares of Sarepta Therapeutics by 154.0% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 154 shares in the last quarter. Fifth Third Bancorp boosted its stake in shares of Sarepta Therapeutics by 1,215.8% in the fourth quarter. Fifth Third Bancorp now owns 1,000 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 924 shares during the last quarter. Hudson Capital Management LLC purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth approximately $206,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in Sarepta Therapeutics by 96.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,397 shares of the biotechnology company’s stock valued at $291,000 after purchasing an additional 1,176 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 761 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the sale, the director now owns 7,516 shares in the company, valued at approximately $923,941.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 761 shares of Sarepta Therapeutics stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the transaction, the director now directly owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Bilal Arif sold 2,000 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the sale, the insider now directly owns 26,836 shares in the company, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. Insiders sold a total of 22,096 shares of company stock worth $2,739,419 over the last ninety days. Company insiders own 7.40% of the company’s stock.

Sarepta Therapeutics Trading Up 1.2 %

NASDAQ SRPT opened at $116.96 on Tuesday. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $159.89. The stock has a market capitalization of $10.98 billion, a P/E ratio of -19.11 and a beta of 0.94. The firm’s 50-day moving average is $126.32 and its two-hundred day moving average is $110.26. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.95 and a quick ratio of 3.45.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.50. The firm had revenue of $396.80 million during the quarter, compared to analysts’ expectations of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The firm’s quarterly revenue was up 53.6% on a year-over-year basis. During the same quarter last year, the company posted ($1.24) EPS. On average, sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 2.13 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on SRPT shares. Royal Bank of Canada lifted their target price on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. Mizuho upped their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. Wedbush reiterated an “outperform” rating and issued a $224.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 29th. Barclays boosted their target price on Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, February 29th. Finally, UBS Group upped their price target on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $158.38.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.